InnoCare Pharma Limited announced that its Board of Directors will convene on 23 April 2026 to review and approve the unaudited consolidated results for the three-month period ended 31 March 2026. The meeting will also address matters related to the publication of these first-quarter figures.
The notice, dated 10 April 2026, confirms the participation of Chairperson and Executive Director Dr. Jisong Cui, alongside other executive, non-executive and independent non-executive directors.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments